Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression

Takahashi, Kou; Murasawa, Hiroyasu; Yamaguchi, Kazumasa; Yamada, Mitsunori; Nakatani, Akiko; Yoshida, Masumi; Iwai, Takashi; Inagaki, Masumi; Saitoh, Akiyoshi

doi:10.1016/j.bbr.2010.07.002

Cited by 37 publications

(24 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of this, few studies of rodent models of depression exist for direct comparison. Takahashi et al (2011) demonstrated that a single dose of riluzole (10 mg/kg, p.o.) significantly decreased resting glutamate levels in the PFC of olfactory bulbectomized rats by in vivo microdialysis.…”

Section: Discussionmentioning

confidence: 99%

Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat: A Genetic Rodent Model of Depression

Hascup

Stephens

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

Despite the numerous drugs targeting biogenic amines for major depressive disorder (depression), the search for novel therapeutics continues because of their poor response rates (B30%) and slow onset of action (2-4 weeks). To better understand role of glutamate in depression, we used an enzyme-based microelectrode array (MEA) that was selective for glutamate measures with fast temporal (2 Hz) and high spatial (15 Â 333 mm) resolution. These MEAs were chronically implanted into the prefrontal cortex of 3-to 6-month-old and 12-to 15-month-old Flinders Sensitive Line (FSL) and control Flinders Resistant Line (FRL) rats, a validated genetic rodent model of depression. Although no changes in glutamate dynamics were observed between 3 and 6 months FRL and FSL rats, a significant increase in resting glutamate levels was observed in the 12-to 15-month-old FSL rats compared with the 3-to 6-month-old FSL and age-matched FRL rats on days 3-5 post-implantation. Our MEA also recorded, for the first time, a unique phenomenon in all the four rat groups of fluctuations in resting glutamate, which we have termed glutamate transients. Although these events lasted only for seconds, they did occur throughout the testing paradigm. The average concentration of these glutamate-burst events was significantly increased in the 12-to 15-month-old FSL rats compared with 3-to 6-month-old FSL and age-matched FRL rats. These studies lay the foundation for future studies of both tonic and phasic glutamate signaling in rat models of depression to better understand the potential role of glutamate signaling in depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat: A Genetic Rodent Model of Depression

Hascup

Stephens

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…83,84 Riluzole, a drug currently used for slowing the progression of amyotrophic lateral sclerosis (ALS), reduced the hyperemotional responses in OBX rats and significantly lowered the glutamate levels in the frontal cortex after a single injection. 85 This drug decreases glutamate release and increases glutamate uptake. It also enhances the Croat.…”

Section: Glutamate System Alteration In Obx Ratsmentioning

confidence: 99%

“…Acta 84 (2011) 287. expression of brain derived neurotrophic factor (BDNF). 85 Because of the exhibited effects, this drug is considered as a potential new antidepressant, with the glutamatergic system playing a role in mood disorders. The N-methyl-D-aspartate glutamate ionotropic receptor (NMDA) has been referred to as a locus of action for antidepressant medication and its reduced number in the cortex and amygdala in OBX rats has been reported.…”

Section: Glutamate System Alteration In Obx Ratsmentioning

confidence: 99%

Neurochemical and Behavioural Changes in Rat Models of Depression

Skelin¹,

Kovačević²,

Dikšić³

2011

Croat. Chem. Acta

View full text Add to dashboard Cite

Abstract. Depression is one of the most prevalent psychiatric disorders with significant lifetime prevalence. The study of human depression is hindered by the relatively significant heterogeneity of this disorder. As a result of these heterogeneities, studies using a sound and representative animal model of depression are extremely valuable and, in general, provide important information regarding the neurochemical/biological changes occurring during depression and the subsequent treatment of its symptoms. In this review we concentrate on two solid rat models of depression: olfactory bulbectomized (OBX) rats and Flinders Sensitive Line (FSL) of rats. These two models were selected because they possess all three characteristics of a good animal model; face, predictive and constructive validities. We also emphasize the brain serotonergic system and we discuss the open field and forced swim test to assess behaviour. (doi: 10.5562/cca1817) Keywords: depression, olfactory bulbectomized rat model of depression, Flinders sensitive line rat, Flinders Resistant line rat, animal model of depression

show abstract

“…These results suggest that dysregulated glutamate transmission, due to pathological astrocytic functional changes, may be involved in depression symptom development. Indeed, the anti-glutamatergic agent, riluzole, has antidepressant effects in depressed patients and animal models of depression [220][221][222][223].…”

Section: Major Depressive Disordermentioning

confidence: 99%

Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease

Takahashi

Foster

Lin

2015

Cell. Mol. Life Sci.

Self Cite

154

111

View full text Add to dashboard Cite

Glutamate is the predominant excitatory neurotransmitter in the central nervous system. Excitatory amino acid transporter 2 (EAAT2) is primarily responsible for clearance of extracellular glutamate to prevent neuronal excitotoxicity and hyperexcitability. EAAT2 plays a critical role in regulation of synaptic activity and plasticity. In addition, EAAT2 has been implicated in the pathogenesis of many central nervous system disorders. In this review, we summarize current understanding of EAAT2, including structure, pharmacology, physiology, and functions, as well as disease relevancy, such as in stroke, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, major depressive disorder, and addiction. A large number of studies have demonstrated that up-regulation of EAAT2 protein provides significant beneficial effects in many disease models suggesting EAAT2 activation is a promising therapeutic approach. Several EAAT2 activators have been identified. Further understanding of EAAT2 regulatory mechanisms could improve development of drug-like compounds that spatiotemporally regulate EAAT2.

show abstract

Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression

Cited by 37 publications

References 47 publications

Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat: A Genetic Rodent Model of Depression

Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat: A Genetic Rodent Model of Depression

Neurochemical and Behavioural Changes in Rat Models of Depression

Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease

Contact Info

Product

Resources

About